Patents Assigned to American National Red Cross
-
Patent number: 6447775Abstract: The present invention relates to methods and compositions for preventing the endocytosis and cellular internalization of integral membrane amyloid &bgr;-precursor protein (APP) and its subsequent catabolism by blocking or interfering with the association or binding of APP with members of the low density lipoprotein receptor family.Type: GrantFiled: November 16, 1999Date of Patent: September 10, 2002Assignees: The General Hospital Corporation, American National Red CrossInventors: Dudley K. Strickland, Bradley T. Hyman, Maria Z. Kounnas, Robert D. Moir, Rudolph E. Tanzi, G. William Rebeck
-
Patent number: 6436344Abstract: The present invention introduces a class of compounds, 2-substituted carbonyl compounds, that are useful as disinfecting agents, and particularly useful in methods for the disinfection of biological fluids. Members of the class of compounds have been found to possess pathogen inactivating properties against a variety of pathogens. The compounds and methods disclosed herein are useful for disinfecting biological fluids such as blood and blood fractions, among others.Type: GrantFiled: November 2, 1999Date of Patent: August 20, 2002Assignees: American National Red Cross, Amersham Pharmacia Biotech ABInventors: Shirley I. Miekka, William H. Drohan, Herbert Baumann, Ingrid Drevin, Jean-Luc Maloisel
-
Publication number: 20010046662Abstract: The invention provides a method for reducing the level of active pathogenic contaminants, such as viruses, bacteria and parasites, found in whole blood and blood components. The method comprises adding to a red blood cell-containing composition at least one phenothiazin-5-ium dye in an amount effective to reduce the level of active pathogenic contaminants and at least one blocking compound in an amount effective to enhance pathogen inactivation and protect red blood cells from hemolysis, and irradiating the red blood cell-containing composition with light of an appropriate intensity and wavelength for a time sufficient to reduce the level of active pathogenic contaminants in the red blood cell-containing composition. An irradiated red blood cell-containing composition comprising red blood cells, a phenothiazin-5-ium dye and a blocking compound is also provided.Type: ApplicationFiled: February 1, 2001Publication date: November 29, 2001Applicant: The American National Red CrossInventors: Stephen J. Wagner, Andrey Skripchenko
-
Patent number: 6320029Abstract: The present invention relates to the preparation and use of liquid formulations of plasma proteins, particularly blood coagulation factors. More specifically, the present invention relates to stable liquid formulations of Factor VIII and Factor IX that can be administered by injection or infusion to provide a constant level of the coagulation factor in the blood.Type: GrantFiled: June 8, 1999Date of Patent: November 20, 2001Assignees: The American National Red Cross, Coalition for Hemophilia B, Inc.Inventors: Shirley I. Miekka, William N. Drohan, Thomas R. Jameson, John R. Taylor, Jr., Manish S. Singh
-
Publication number: 20010031459Abstract: The invention relates to the field of organ and tissue perfusion. More particularly, the present invention relates to a method for preparing organs, such as the kidney and liver, for cryopreservation through the introduction of vitrifiable concentrations of cryoprotectant into them. To prepare the organ for cryopreservation, the donor human or animal, is treated in the usual manner and may also be treated with iloprost, or other vasodilators, and/or transforming growth factor &bgr;1. Alternatively, or additionally, the organ which is to be cryopreserved can be administered iloprost, or other vasodilators, and/or transforming growth factor &bgr;1 directly into its artery. The invention also relates to preparing organs for transplantation by a method for the removal of the cryoprotectant therefrom using low (such as raffinose, sucrose, mannitol, etc.Type: ApplicationFiled: January 12, 2001Publication date: October 18, 2001Applicant: THE AMERICAN NATIONAL RED CROSSInventors: Gregory Fahy, Bijan Khirabadi, Yasumitsu Okouchi, Thomas Maciag
-
Patent number: 6255554Abstract: A non-human transgenic mammalian animal, as described above, contains an exogenous double stranded DNA sequence stably integrated into the genome of the animal, which comprises cis-acting regulatory units operably linked to a DNA sequence encoding human Factor VIII protein and a signal peptide, where the cis-acting regulatory units are active in mammary gland cells and the signal peptide is active in directing newly expressed Factor VIII into the milk of the animal. The promoter may be a milk protein promoter such as for whey acidic protein, casein, lactalbumin, or beta-lactoglobulin promoter. The transgenic mammals are preferably farm animals, for example, cows, goats, sheep, rabbits and pigs. Concurrent expression of a gene for human von Willebrand's Factor into milk may be used to stabilize newly-secreted Factor VIII.Type: GrantFiled: March 4, 1999Date of Patent: July 3, 2001Assignees: American National Red Cross, Virginia Polytechnic Institute & State UniversityInventors: Henryk Lubon, William N. Drohan, William H. Velander
-
Patent number: 6245548Abstract: A method for the production of thrombin from pure prothrombin is provided by converting pure prothrombin by treating pure prothrombin with sodium citrate in the absence of additional coagulation factors. Preferrably, a solution is used containing about 30% to about 40% sodium citrate.Type: GrantFiled: March 9, 2000Date of Patent: June 12, 2001Assignee: American National Red CrossInventors: Annemarie H. Ralston, William N. Drohan
-
Patent number: 6197325Abstract: This invention provides methods for the localized delivery of supplemented tissue sealants, wherein the supplemented tissue sealants comprise at least one composition which is selected from one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, antiproliferatives, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Further provided are methods of using the site-specific supplemented tissue sealants, including preparation of a biomaterial.Type: GrantFiled: June 7, 1995Date of Patent: March 6, 2001Assignee: The American National Red CrossInventors: Martin James MacPhee, William Nash Drohan, Carlos I. Lasa, Jr., Gene Liau, Christian Haudenschild
-
Patent number: 6193891Abstract: The present invention pertains to improved methods for the selective separation of organic components from biological fluids. More particularly, the present invention pertains to methods for the selective separation of organic components from biological fluids which comprise the step of contacting the biological fluid with a synthetic hydrated alkaline earth silicate (i.e., SHAES), such as synthetic hydrated calcium silicate (i.e., SHCS) or synthetic hydrated magnesium silicate (i.e., SHMS). In a preferred embodiment, the present invention pertains to such methods where the biological fluid is a mammalian blood fluid (e.g., whole blood, blood plasma, blood serum, blood fraction, plasma fraction, serum fraction).Type: GrantFiled: December 20, 1996Date of Patent: February 27, 2001Assignee: American National Red CrossInventors: Randall S. Kent, William N. Drohan
-
Patent number: 6187529Abstract: The invention relates to the field of organ and tissue perfusion. More particularly, the present invention relates to a method for preparing organs, such as the kidney and liver, for cryopreservation through the introduction of vitrifiable concentrations of cryoprotectant into them. To prepare the organ for cryopreservation, the donor human or animal, is treated in the usual manner and may also be treated with iloprost, or other vasodilators, and/or transforming growth factor &bgr;1. Alternatively, or additionally, the organ which is to be cryopreserved can be administered iloprost, or other vasodilators, and/or transforming growth factor &bgr;1 directly into its artery. The invention also relates to preparing organs for transplantation by a method for the removal of the cryoprotectant therefrom using low (such as raffinose, sucrose, mannitol, etc.Type: GrantFiled: April 28, 1998Date of Patent: February 13, 2001Assignee: The American National Red CrossInventors: Gregory M. Fahy, Bijan Khirabadi, Yasumitsu Okouchi, Thomas Maciag
-
Patent number: 6156311Abstract: The present invention broadly relates to the treatment, diagnosis, and prophylactic prevention of Alzheimer's disease. More specifically, the present invention relates to methods and compositions for preventing the endocytosis and cellular internalization of integral membrane amyloid .beta.-precursor protein (APP) and its subsequent catabolism by blocking or interfering with the association or binding of APP with members of the low density lipoprotein receptor family.Type: GrantFiled: July 26, 1996Date of Patent: December 5, 2000Assignees: The American National Red Cross, The General Hospital CorporationInventors: Dudley K. Strickland, Bradley T. Hyman, Maria Z. Kounnas, Robert D. Moir, Rudolph E. Tanzi
-
Patent number: 6124273Abstract: This invention is directed to the preparation and utilization of supplemented chitin hydrogels, such as chitosan hydrogels. Further provided are biomaterials comprising same. The particular supplement delivered by the chitin hydrogel is selected as a function of its intended use. In one embodiment, this invention provides a composition of matter, comprising a chitin hydrogel or chitin-derived hydrogel, wherein the hydrogel does not inhibit full-thickness skin wound healing.Type: GrantFiled: October 13, 1997Date of Patent: September 26, 2000Assignees: Chitogenics, Inc., The American National Red Cross, Coalition for Hemophilia BInventors: William N. Drohan, Martin J. MacPhee, Shirley I. Miekka, Manish S. Singh, Clive Elson, John R. Taylor, Jr.
-
Patent number: 6117425Abstract: This invention provides supplemented tissue sealants, methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one cytotoxin or cell proliferation inhibiting composition. The composition may be further supplemented with, for example, one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, cytokines, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.Type: GrantFiled: June 7, 1995Date of Patent: September 12, 2000Assignee: The American National Red CrossInventors: Martin James MacPhee, William Nash Drohan, Gene Liau, Christian Haudenschild
-
Patent number: 6106773Abstract: The present invention is directed to pathogen inactivating compositions that can be used to disinfect various biological fluids, such as blood, blood fractions, and the like. The compositions are suitable for disinfecting biological fluids containing valuable, but labile, components such as proteins without destroying the desired properties of such components. The pathogen inactivating compositions of the present invention are produced by contacting water or an aqueous solution with iodinated matrix material. The compositions can be pre-formulated and stored for subsequent use in disinfecting a wide range of biological fluids.Type: GrantFiled: September 24, 1998Date of Patent: August 22, 2000Assignee: American National Red CrossInventors: Shirley I. Miekka, William N. Drohan, Annemarie Ralston, Hao Xue
-
Patent number: 6103498Abstract: Mutants of the human PAI-1 protein are described which are inhibitors of neutrophil elastase or are inhibitors of vitronectin (Vn)-dependent cell migration. These mutants preferably comprise one or two amino acid substitutions in the reactive center loop of PAI-1, particularly at positions 331 and 346 of the mature protein. These mutants are notable in being resistant to inactivation by elastase, having high affinity for Vn, or both properties. These mutant proteins as pharmaceutical compositions are used to inhibit elastase in a subject, thereby treating a number of disorders associated with elastase activity, most notably emphysema, ARDS, inflammatory lung injury and cystic fibrosis. The mutants which interact with Vn are used to inhibit cell migration in a subject, thereby treating diseases or conditions associated with undesired cell migration and proliferation, particularly of smooth muscle cells.Type: GrantFiled: April 11, 1997Date of Patent: August 15, 2000Assignee: American National Red CrossInventors: Daniel A. Lawrence, Steingrimur P. Stefansson
-
Patent number: 6096216Abstract: The present invention provides media for inactivating pathogens found within protein-containing biological fluids. The media of the present invention preserve the structural integrity and biological activity of labile proteins while simultaneously exhibiting potent disinfectant activity. The media of the present invention comprise iodinated chromatographic media, particularly ion exchange media. The invention further provides methods for disinfecting biological fluids.Type: GrantFiled: March 7, 1997Date of Patent: August 1, 2000Assignees: American National Red Cross, Amersham Pharmacia Biotech, Inc., Edward ShanbromInventors: Edward Shanbrom, Shirley I. Miekka, Robert Pollock, William N. Drohan, Timothy W. Horton
-
Patent number: 6093804Abstract: The methods of the present invention provide a simple means for separating active and inactive Alpha Proteinase Inhibitor (API). The methods further provide means for purifying API at high yield (>70%), and at levels of purity (>90%) and activity (>90%) not heretofore available. Moreover, the methods of the present invention are simple (i.e., two chromatographic steps) and efficient; and are thus especially suitable to large scale purification processes. These methods will contribute substantially to alleviating the unmet demand for API for therapeutic purposes.Type: GrantFiled: September 24, 1998Date of Patent: July 25, 2000Assignee: American National Red CrossInventors: Annemarie H. Ralston, William H. Drohan
-
Patent number: 6054122Abstract: This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and/or using the unsupplemented or supplemented fibrin sealant dressing.Type: GrantFiled: June 7, 1995Date of Patent: April 25, 2000Assignee: The American National Red CrossInventors: Martin James MacPhee, William Nash Drohan, Christoper J. Woolverton
-
Patent number: 6030767Abstract: This invention is directed to a method for inactivating pathogenic contaminants, such as viruses, bacteria, parasites and leukocytes, frequently found in whole blood or blood components, such as red blood cells or plasma, which comprises treating whole blood or blood components with an amphiphilic phenothiazin-5-ium dye and light. Preferred amphiphilic phenothiazin-5-ium dyes are those having the formula ##STR1## wherein each of R.sub.1, R.sub.1 ', R.sub.2, and R.sub.2 ' is independently selected from the group consisting of an alkyl group, an alkenyl group, an alkynyl group, a nitrile, an aralkyl group, a hydroxy group, an alkoxy group, an amine group, and a hydrogen atom, each of R.sub.3, R.sub.3 ', R.sub.4, R.sub.4 ', R.sub.5 and R.sub.Type: GrantFiled: January 21, 1998Date of Patent: February 29, 2000Assignees: The American National Red Cross, The Rowland Institute for ScienceInventors: Stephen J. Wagner, Louis Cincotta
-
Patent number: 5962214Abstract: The invention relates to the field of organ and tissue perfusion. More particularly, the present invention relates to a method for preparing organs, such as the kidney and liver, for cryopreservation through the introduction of vitrifiable concentrations of cryoprotectant into them. To prepare the organ for cryopreservation, the donor human or animal, is treated in the usual manner and may also be treated with iloprost, or other vasodilators, and/or transforming growth factor .beta.1. Alternatively, or additionally, the organ which is to be cryopreserved can be administered iloprost, or other vasodilators, and/or transforming growth factor .beta.1 directly into its artery. The invention also relates to preparing organs for transplantation by a method for the removal of the cryoprotectant therefrom using low (such as raffi nose, sucrose, mannitol, etc.Type: GrantFiled: February 27, 1998Date of Patent: October 5, 1999Assignee: The United States of America as represented by The American National Red CrossInventors: Gregory M. Fahy, Bijan Khirabadi, Yasumitsu Okouchi, Thomas Maciag